TOP > クイック検索 > 外国特許検索 > Anti-influenza virus agent and screening method for anti-influenza virus agent

Anti-influenza virus agent and screening method for anti-influenza virus agent NEW

外国特許コード F190009715
整理番号 E096P07US2
掲載日 2019年1月24日
出願国 アメリカ合衆国
出願番号 201816113150
公報番号 20180360819
出願日 平成30年8月27日(2018.8.27)
公報発行日 平成30年12月20日(2018.12.20)
国際出願番号 JP2015076674
国際公開番号 WO2016047592
国際出願日 平成27年9月18日(2015.9.18)
国際公開日 平成28年3月31日(2016.3.31)
優先権データ
  • 特願2014-192752 (2014.9.22) JP
  • 2015JP76674 (2015.9.18) WO
  • 201715511930 (2017.3.16) US
発明の名称 (英語) Anti-influenza virus agent and screening method for anti-influenza virus agent NEW
発明の概要(英語) The present invention provides an anti-influenza virus agent that targets biomolecules of host cells including human cells and a method of screening a candidate molecule for the anti-influenza virus agent.That is, the present invention is an anti-influenza virus agent that has an effect of suppressing expression or a function of a gene that encodes a protein having an effect of suppressing incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells and the gene is at least one selected from the group including JAK1 gene and the like.
従来技術、競合技術の概要(英語) BACKGROUND ART
Influenza viruses cause epidemic diseases every year and sometimes cause pandemic diseases taking millions of victims.Therefore, the development of more effective anti-influenza virus agents is necessary.As target molecules of anti-influenza virus agents, biomolecules of host cells that contribute to infection and replication of viruses are more preferable than virus proteins.This is because biomolecules of host cells are less prone to mutation due to drug selective pressure than virus proteins.
In recent years, by 6 types of genome-wide screening, a total of 1449 human genes (including human orthologs of 110 fly (Drosophila)genes) that are considered to play some role in the influenza virus life cycle have been identified (refer to Non Patent Literatures 1 to 6).Although genome-wide screening results only partially match, the reason for this is speculated to be related to the different experimental conditions.
特許請求の範囲(英語) [claim1]
1. An influenza treatment method comprising administering an effective amount of an anti-influenza virus agent to an animal infected with an influenza virus,
wherein the anti-influenza virus agent has an effect of suppressing expression of a gene that encodes a protein involved in incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells or an effect of suppressing a function of the protein, and
wherein the gene is at least one selected from the group consisting of JAK1 gene, CHERP gene, DDX21 gene, DNAJC11 gene, EEF1A2 gene, HNRNPK gene, ITM2B gene, MRCL3 gene, MYH10 gene, NDUFS8 gene, PSMD13 gene, RPL26 gene, SDF2L1 gene, SDF4 gene, SFRS2B gene, SNRPC gene, SQSTM1 gene, TAF15 gene, TOMM40 gene, TRM2B gene, USP9X gene, BASP1 gene, THOC2 gene, PPP6C gene, TESC gene, and PCDHB12 gene.
[claim2]
2. The influenza treatment method according to claim 1,
wherein the gene is JAK1 gene or USP9X gene.
[claim3]
3. The influenza treatment method according to claim 1,
wherein the anti-influenza virus agent is at least one selected from the group consisting of Ruxolitinib, Tofacitinib, Tofacitinib (CP-690550) Citrate, Tyrphostin B42 (AG-490), Baricitinib (LY3009104, INCB028050), AT9283, Momelotinib, CEP33779, NVP-BSK805, ZM39923, Filgotinib, JANEX-1, NVP-BSK805, SB1317, and WP1130.
[claim4]
4. An influenza treatment method comprising administering an effective amount of an anti-influenza virus agent to an animal infected with an influenza virus,
wherein the anti-influenza virus agent has an effect of suppressing expression of a gene that encodes a protein involved in influenza virus replication or transcription in host cells or an effect of suppressing a function of the protein, and
wherein the gene is at least one selected from the group consisting of CCDC56 gene, CLTC gene, CYC1 gene, NIBP gene, ZC3H15 gene, C14orf173 gene, ANP32B gene, BAG3 gene, BRD8 gene, CCDC135 gene, DDX55 gene, DPM3 gene, EEF2 gene, IGF2BP2 gene, KRT14 gene, and S100A4 gene.
[claim5]
5. An influenza treatment method comprising administering an effective amount of an anti-influenza virus agent to an animal infected with an influenza virus,
wherein the anti-influenza virus agent has an effect of suppressing expression of a gene that encodes a protein involved in formation of influenza virus-like particles in host cells or an effect of suppressing a function of the protein, and
wherein the gene is at least one selected from the group consisting of GBF1 gene, ASCC3L1 gene, BRD8 gene, C19orf43 gene, DDX55 gene, DKFZp564K142 gene, DPM3 gene, EEF2 gene, FAM73B gene, FLJ20303 gene, NCLN gene, C14orf173 gene, LRPPRC gene, and RCN1 gene.
[claim6]
6. The influenza treatment method according to claim 5,
wherein the gene is GBF1 gene.
[claim7]
7. The influenza treatment method according to claim 5,
wherein the anti-influenza virus agent is Golgicide A.
[claim8]
8. A screening method for an anti-influenza virus agent which is a method of screening a candidate compound for an anti-influenza virus agent,
wherein a compound capable of suppressing or inhibiting expression of a gene that is at least one selected from the group consisting of JAK1 gene, CHERP gene, DDX21 gene, DNAJC11 gene, EEF1A2 gene, HNRNPK gene, ITM2B gene, MRCL3 gene, MY10 gene, NDUFS8 gene, PSMD13 gene, RPL26 gene, SDF2L1 gene, SDF4 gene, SFRS2B gene, SNRPC gene, SQSTM1 gene, TAF15 gene, TOM40 gene, TRM2B gene, USP9X gene, BASP1 gene, THOC2 gene, PPP6C gene, TESC gene, PCDHB12 gene, CCDC56 gene, CLTC gene, CYC1 gene, NIBP gene, ZC3H15 gene, C14orf173 gene, ANP32B gene, BAG3 gene, BRD8 gene, CCDC135 gene, DDX55 gene, DPM3 gene, EEF2 gene, IGF2BP2 gene, KRT14 gene, S100A4 gene, GBF1 gene, ASCC3L1 gene, C19orf43 gene, DKFZp564K142 gene, FAM73B gene, FLJ20303 gene, NCLN gene, LRPPRC gene, and RCNI gene or a function of a protein that the gene encodes is screened as the candidate compound for the anti-influenza virus agent.
[claim9]
9. The screening method for an anti-influenza virus agent according to claim 8, comprising:
a process in which a target compound to be evaluated as a candidate compound for an anti-influenza virus agent is introduced into cells;
a process in which an expression level of the gene in the cells into which the compound is introduced is measured; and
a process in which, when the expression level of the gene is significantly lower than that of cells into which the compound is not yet introduced, the compound is selected as the candidate compound for the anti-influenza virus agent.
[claim10]
10. The screening method for an anti-influenza virus agent according to claim 8,
wherein the protein that the gene encodes is an enzyme, and
wherein the screening method includes
a process in which enzyme activity of the protein that the gene encodes is measured under the presence of a target compound to be evaluated as a candidate compound for an anti-influenza virus agent; and
a process in which, when the enzyme activity of the protein in the presence of the compound is lower than that in the absence of the compound, the compound is selected as the candidate compound for the anti-influenza virus agent.
  • 発明者/出願人(英語)
  • KAWAOKA Yoshihiro
  • WATANABE Tokiko
  • KAWAKAMI Eiryo
  • WATANABE Shinji
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
国際特許分類(IPC)
参考情報 (研究プロジェクト等) ERATO KAWAOKA Infection-induced Host Responses AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close